DENVER, March 20 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test at the American College of Cardiology (ACC) 57th Annual Scientific Session Exposition. The annual meeting takes place March 29-April 1, 2008, at the McCormick Place Convention Center in Chicago, Ill.
Corgenix representatives will be on-hand during ACC 2008 at booth 4106 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information.
AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.
"ACC 2008 represents one of the most prestigious gatherings of cardiovascular professionals in the nation and an opportunity for us to further educate the medical community about the AspirinWorks test," said Corgenix' Clinical Affairs Director Gordon Ens. "We're looking forward to demonstrating the value of more clearly understanding a patient's individual response to aspirin."
The AspirinWorks Test, which was launched in the United States in June
2007 following FDA 510(k) clearance, is now available nationwide through
major medical reference laboratories, as well as direct to consumers
through HealthCheckUSA (http://www.Heal
|SOURCE Corgenix Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved